Press Release Nov 26 2025
Filed with NSE · · 6 pages · English
Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: [email protected] CIN: L24230GJ1993PLC019050 26 November 2025 Enclosed herewith are the copies of the press releases titled “FDA approves label update for UNLOXCYT™ (c
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
- Press Release Nov 17 2025
- Press Release Nov 12 2025
- Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®
- Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
Later from Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries Limited Press Release Dec 01 2025
- Sun Pharma Launches ILUMYA® In India
- ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis
- Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Press Release Jan 15 2026
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries